1. Home
  2. Directory
  3. Texas
  4. Dallas
  5. Ophthalmology
  6. NPI Profile
  7. Prescriptions 1083175558

ABIGAIL ANNETTE GORDON
Prescription History 1083175558
Ophthalmology in Dallas, TX


Quality Rating: 74.59 out of 100 score

NPI Status: Active since March 27, 2019

Contact Information

5323 HARRY HINES BLVD
DALLAS, TX
ZIP 75390
Phone: (214) 648-3111

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ABIGAIL ANNETTE GORDON, an active Ophthalmology specialist practicing in Dallas, TX. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 163 documented patient claims. Among these therapy options, the most frequently utilized medication is Tramadol Hcl, which accounts for 41 claims alone.

Medication Index

B
C
E
T
No matching medications currently found on file.

Bacitracin-Polymyxin

Generic Formulation: Bacitracin/Polymyxin B SulfateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 35
30-Day Fills 35.0
Days Supply 474
TX State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills38.7
Peer Average Days Supply486
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $646.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.48

State Avg Cost Per Claim

$15.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat eye infections. This product contains bacitracin and polymyxin, antibiotics that work by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Cephalexin

Generic Formulation: CephalexinSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 161
TX State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills32.5
Peer Average Days Supply368
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $145.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.33

State Avg Cost Per Claim

$9.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Erythromycin

Generic Formulation: Erythromycin BaseSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 34
30-Day Fills 34.0
Days Supply 343
TX State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills54.8
Peer Average Days Supply750
Conservative Utilization

This provider writes prescriptions for this formulation 35.8% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $502.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.77

State Avg Cost Per Claim

$17.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Erythromycin is used to treat a wide variety of bacterial infections. It may also be used to prevent certain bacterial infections. Erythromycin is known as a macrolide antibiotic. It works by stopping the growth of bacteria. This antibiotic treats or prevents only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Tobramycin

Generic Formulation: TobramycinSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 30
30-Day Fills 30.0
Days Supply 362
TX State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills34.8
Peer Average Days Supply652
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $176.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.87

State Avg Cost Per Claim

$7.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.

Therapeutic Applications

This medication is used to treat people with a certain inherited condition (cystic fibrosis) who have an ongoing lung infection with a certain bacteria (Pseudomonas aeruginosa). People with cystic fibrosis produce thick, sticky mucus that can plug up the tubes, ducts and passageways in the lungs. This can result in serious breathing problems and infections in the lungs. Tobramycin belongs to a class of drugs known as aminoglycoside antibiotics. Tobramycin inhalation solution works by stopping the growth of a certain bacteria (Pseudomonas aeruginosa) that commonly infects the lungs of people with cystic fibrosis. This effect decreases lung infections and damage, and helps to improve breathing.

Tramadol Hcl

Generic Formulation: Tramadol HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 41
30-Day Fills 41.0
Days Supply 204
TX State Average Benchmarks
Peer Average Claims62.0
Peer Average 30-Day Fills63.6
Peer Average Days Supply1,282
Conservative Utilization

This provider writes prescriptions for this formulation 33.9% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $104.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$2.54

State Avg Cost Per Claim

$7.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A narcotic analgesic proposed for severe pain. It may be habituating.

Therapeutic Applications

See also Warning section. This medication is used to help relieve moderate to moderately severe pain. Tramadol belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ABIGAIL ANNETTE GORDON provides transparency into local medical care patterns within Dallas, TX.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Ophthalmology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.